Medline Sees Unusually Large Options Volume (NASDAQ:MDLN)

Medline (NASDAQ:MDLN – Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Stock traders purchased 10,954 call options on the company. This represents an increase of approximately 289% compared to the typical daily volume of 2,819 call options.

Medline Trading Down 3.4%

Shares of MDLN opened at $37.84 on Friday. Medline has a 1-year low of $31.37 and a 1-year high of $50.88. The company has a current ratio of 4.04, a quick ratio of 2.51 and a debt-to-equity ratio of 0.65. The firm’s 50-day moving average price is $35.60 and its 200-day moving average price is $39.25. The firm has a market capitalization of $49.77 billion and a price-to-earnings ratio of 32.36.

Medline (NASDAQ:MDLN – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.32 by $0.12. Medline had a net margin of 1.84% and a return on equity of 8.21%. The company had revenue of $7.86 billion during the quarter. Sell-side analysts anticipate that Medline will post 1.58 EPS for the current year.

Key Medline News

These are some of the MDLN news items that stood out recently:

  • Positive Sentiment: Several recent valuation articles argue Medline may be undervalued, estimating upside of about 19% to 33%; a separate report says analysts raised fair-value estimates. These are valuation opinions, not guarantees of future performance. Article Article Article
  • Positive Sentiment: Medline and its holding company plan a $200 million repurchase alongside the offering, providing some demand for shares, although the buyback is conditional on the offering closing. Company announcement
  • Negative Sentiment: Medline has reported additional deaths in connection with its electric-bed recall, raising potential product-liability and reputational concerns. Separately, a law firm announced a securities-fraud investigation; this is an investigation announcement, not a finding of wrongdoing. Article Investigation announcement

Wall Street Analysts Forecast Growth

MDLN has been the subject of a number of recent analyst reports. Weiss Ratings raised Medline from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, November 9th. Tigress Financial dropped their price objective on Medline from $62.00 to $55.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Truist Financial cut their price objective on Medline from $56.00 to $47.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Leerink Partners boosted their target price on Medline from $43.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. Finally, TD Cowen decreased their target price on Medline from $53.00 to $45.00 and set a “buy” rating for the company in a report on Monday, August 10th. Twenty-three analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $46.08.

View Our Latest Analysis on MDLN

Insider Activity at Medline

In other news, major shareholder Private Ltd Gic sold 2,570,999 shares of the company’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $35.35, for a total transaction of $90,884,814.65. Following the completion of the transaction, the insider directly owned 20,231,483 shares of the company’s stock, valued at approximately $715,182,924.05. This represents a 11.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold 6,348,676 shares of company stock worth $224,525,137 over the last ninety days. Corporate insiders own 0.81% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in MDLN. GAMMA Investing LLC increased its stake in shares of Medline by 68.3% during the second quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock valued at $25,000 after purchasing an additional 254 shares in the last quarter. Reyes Financial Architecture Inc. purchased a new position in shares of Medline during the third quarter valued at approximately $30,000. NewEdge Advisors LLC lifted its holdings in shares of Medline by 100.0% during the second quarter. NewEdge Advisors LLC now owns 950 shares of the company’s stock valued at $37,000 after purchasing an additional 475 shares during the last quarter. Allworth Financial LP boosted its position in shares of Medline by 86.2% in the 2nd quarter. Allworth Financial LP now owns 1,052 shares of the company’s stock worth $41,000 after purchasing an additional 487 shares in the last quarter. Finally, Flputnam Investment Management Co. bought a new stake in shares of Medline in the 3rd quarter worth approximately $43,000.

About Medline

(Get Free Report)

Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.

Featured Stories

Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.